Dominari (NASDAQ:DOMH) Releases Quarterly Earnings Results

Dominari (NASDAQ:DOMH) released its earnings results on Monday. The company reported ($0.11) EPS for the quarter, Zacks reports. Dominari had a negative return on equity of 94.32% and a negative net margin of 36.01%.The company had revenue of $50.82 million for the quarter.

Dominari Stock Performance

Shares of DOMH traded up $0.19 during trading hours on Wednesday, hitting $5.65. The stock had a trading volume of 49,093 shares, compared to its average volume of 732,825. The firm has a market cap of $90.39 million, a P/E ratio of -2.38 and a beta of 0.66. Dominari has a 12-month low of $0.83 and a 12-month high of $13.58. The company’s fifty day simple moving average is $6.08 and its 200 day simple moving average is $5.63.

Dominari Announces Dividend

The business also recently declared a special dividend, which was paid on Friday, September 26th. Shareholders of record on Wednesday, September 3rd were paid a dividend of $0.22 per share. The ex-dividend date of this dividend was Wednesday, September 3rd.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Jane Street Group LLC purchased a new position in Dominari in the second quarter valued at about $158,000. Geode Capital Management LLC raised its position in shares of Dominari by 2.9% during the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company’s stock worth $361,000 after purchasing an additional 1,866 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Dominari by 8.0% during the 3rd quarter. Vanguard Group Inc. now owns 345,896 shares of the company’s stock valued at $2,452,000 after purchasing an additional 25,694 shares during the period. 42.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently commented on DOMH. Wall Street Zen upgraded Dominari from a “sell” rating to a “buy” rating in a research report on Saturday, August 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dominari in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Dominari has a consensus rating of “Sell”.

Dominari Company Profile

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.